Company news
Urogen Pharma Ltd. (NASDAQ:URGN) news
Urogen Pharma Ltd. news releases on 6ix. Latest, Nov 10, 2021: UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
Press releases — page 4
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
November 9, 2021
UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
October 31, 2021
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
October 4, 2021
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
September 12, 2021
UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 9, 2021
UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
August 3, 2021
UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021
July 27, 2021
UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel
July 27, 2021
UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021
July 13, 2021
UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference
July 6, 2021
UroGen Pharma Announces June 2021 Conference Schedule
May 24, 2021
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
May 12, 2021
UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
May 5, 2021
UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments
March 17, 2021
UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments
March 17, 2021
UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline
March 14, 2021
UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021
March 10, 2021
UroGen Pharma Announces March 2021 Conference Schedule
February 22, 2021
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
January 12, 2021
UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021
UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology
December 2, 2020
Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
November 16, 2020
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021
November 10, 2020
UroGen Pharma Announces November 2020 Conference Schedule
November 9, 2020
UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments
November 8, 2020
UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020
November 1, 2020
UroGen Pharma Announces September 2020 Conference Schedule
September 9, 2020
UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth
September 8, 2020
UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence
August 26, 2020
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments
August 9, 2020
UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
August 2, 2020
UroGen Pharma to Present at Jefferies Virtual Healthcare Conference
May 31, 2020
UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer
May 14, 2020
UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer
May 14, 2020
UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments
May 6, 2020
UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020
April 30, 2020
The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial
April 29, 2020
UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer
April 14, 2020
UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
April 2, 2020
UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development
March 22, 2020
UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments
March 1, 2020
UroGen Pharma Announces March 2020 Investor Conference Schedule
February 24, 2020
UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101
December 18, 2019
UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments
November 11, 2019
UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers
November 10, 2019
UroGen Pharma to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
November 5, 2019
UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer
September 23, 2019
UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness
September 9, 2019